Dana-Farber Cancer Institute

Patients with depression had a 37% higher risk of dying from their disease than patients without a mental health diagnosis.

This and previous research from the Sethi Lab suggest Sox9 is a promising therapeutic target for colorectal cancer.

Dana-Farber Cancer Institute, one of the world’s leading cancer research and treatment centers, has partnered with the Parker Institute for Cancer Immunotherapy, the leading network of immuno-oncology expertise in the world, as a member of the PICI Network with a goal to better understand the tumor microenvironment across cancer types and translate these basic discoveries to the clinic as impactful cancer immunotherapies.